Latest Research And Development News

ClearVue Technologies and LandGlass subsidiary LandVac have entered a strategic partnership to co-develop and commercialize advanced solar vacuum insulated glazing products, aiming to revolutionize energy-efficient building materials worldwide.

Island Pharmaceuticals has accelerated its acquisition of the Galidesivir antiviral program from BioCryst Pharmaceuticals, adding a clinically advanced asset with significant US government backing and a promising regulatory pathway.

Sparc Technologies progresses its pioneering green hydrogen pilot plant and graphene-based coatings, backed by a significant government grant and a successful capital raise.

Orthocell Limited has reported a record FY2025 revenue of A$9.19 million, driven by strong sales of its nerve repair product Remplir™ in Australia and a promising US market launch following FDA clearance.

DroneShield Limited has landed a significant $11.7 million follow-on research contract from a Five Eyes Department of Defence customer, marking its fourth award from this strategic alliance.

Janus Electric has secured a three-year supply deal with Electrovaya to develop advanced lithium-ion battery packs, promising safer, longer-lasting, and lighter batteries for zero-emission heavy vehicles.

Netlinkz Limited has officially launched its Securelink joint venture in the Philippines, marking a strategic pivot towards ASEAN markets while progressing a debt restructure and capital raise to support growth and an ASX relisting.

Imugene Limited has received a $5.87 million R&D tax refund, reinforcing its capacity to advance clinical trials in immuno-oncology. This funding milestone supports the development of its innovative cancer therapies, including CAR T cell treatments and oncolytic virotherapy.

Acrux Limited has secured a further $0.46 million advance on its FY25 R&D Tax Incentive, bringing total advances to $2.19 million and supporting its pharmaceutical product development and working capital needs.

BPH Global has launched a focused R&D collaboration with Temasek Polytechnic to develop seaweed-based bio-stimulants aimed at boosting growth and yields in Southeast Asia's oil palm and rice sectors. Early talks are also underway for a production facility in Indonesia to commercialize these innovations.

Rhythm Biosciences has obtained a $1 million non-dilutive loan backed by its FY2025 R&D Tax Incentive rebate, aiming to accelerate the commercial rollout of its ColoSTAT® test and expand its geneType™ platform.

ClearVue Technologies has secured $746,574 through a mix of equity and debt to support its international commercialisation efforts amid shifting market conditions.